| Gabapentin | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Gabapentin | hsa00230 | Purine metabolism | 4.48E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
| Gabapentin | hsa00500 | Starch and sucrose metabolism | 1.34E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
| Gabapentin | hsa00531 | Glycosaminoglycan degradation | 8.18E-04 | 2 | P15586, P34059 | GNS, GALNS | More | |
| Gabapentin | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 2.92E-02 | 1 | Q9Y2C2 | UST | More | |
| Gabapentin | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | |
| Gabapentin | hsa00730 | Thiamine metabolism | 3.83E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Gabapentin | hsa00830 | Retinol metabolism | 3.19E-02 | 1 | P00325 | ADH1B | More | |
| Gabapentin | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Gabapentin | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Gabapentin | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
| Gabapentin | hsa01522 | Endocrine resistance | 6.51E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
| Gabapentin | hsa03008 | Ribosome biogenesis in eukaryotes | 2.06E-02 | 2 | Q9NYH9, Q9BVP2 | UTP6, GNL3 | More | |
| Gabapentin | hsa03020 | RNA polymerase | 9.80E-05 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | |
| Gabapentin | hsa03040 | Spliceosome | 1.46E-02 | 4 | P17844, P51991, P61978, P11142 | DDX5, HNRPA3, HNRPK, HSPA8 | More | |
| Gabapentin | hsa03050 | Proteasome | 1.20E-02 | 2 | P55036, P40306 | PSMD4, PSMB10 | More | |
| Gabapentin | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
| Gabapentin | hsa04015 | Rap1 signaling pathway | 3.69E-04 | 5 | P15498, Q08828, P51828, P31751, P0DP23 | VAV1, ADCY1, ADCY7, AKT2, CALM1 | More | |
| Gabapentin | hsa04020 | Calcium signaling pathway | 1.42E-02 | 3 | Q08828, P0DP23, P51828 | ADCY1, CALM1, ADCY7 | More | |
| Gabapentin | hsa04022 | cGMP-PKG signaling pathway | 2.66E-03 | 4 | P31751, Q08828, P51828, P0DP23 | AKT2, ADCY1, ADCY7, CALM1 | More | |
| Gabapentin | hsa04024 | cAMP signaling pathway | 6.94E-05 | 5 | Q08828, P51828, P31751, P0DP23, P15498 | ADCY1, ADCY7, AKT2, CALM1, VAV1 | More | |
| Gabapentin | hsa04062 | Chemokine signaling pathway | 7.23E-03 | 4 | P15498, Q08828, P51828, P31751 | VAV1, ADCY1, ADCY7, AKT2 | More | |
| Gabapentin | hsa04071 | Sphingolipid signaling pathway | 8.46E-04 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | |
| Gabapentin | hsa04072 | Phospholipase D signaling pathway | 1.67E-02 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
| Gabapentin | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Gabapentin | hsa04114 | Oocyte meiosis | 1.67E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
| Gabapentin | hsa04141 | Protein processing in endoplasmic reticulum | 1.91E-03 | 6 | P18848, Q15437, Q99941, P11142, P07900, Q9NR31 | ATF4, SEC23B, CREBL1, HSPA8, HSP90AA1, SAR1A | More | |
| Gabapentin | hsa04142 | Lysosome | 1.14E-02 | 3 | P43234, P15586, P34059 | CTSO, GNS, GALNS | More | |
| Gabapentin | hsa04151 | PI3K-Akt signaling pathway | 3.91E-03 | 7 | P62753, P27348, P07900, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, TNXB, CREBL1, ATF4, SGK | More | |
| Gabapentin | hsa04210 | Apoptosis | 9.18E-03 | 4 | P04637, P24522, P43234, P63261 | TP53, GADD45A, CTSO, ACTG1 | More | |
| Gabapentin | hsa04211 | Longevity regulating pathway | 5.35E-04 | 5 | P31751, Q08828, P51828, Q99941, P18848 | AKT2, ADCY1, ADCY7, CREBL1, ATF4 | More | |
| Gabapentin | hsa04213 | Longevity regulating pathway - multiple species | 2.91E-03 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
| Gabapentin | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.82E-05 | 10 | P07550, Q08828, P51828, P22694, P31751, Q99941, P18848, Q13362, P0DP23, Q13557 | ADRB2, ADCY1, ADCY7, PRKACB, AKT2, CREBL1, ATF4, PPP2R5C, CALM1, CAMK2D | More | |
| Gabapentin | hsa04270 | Vascular smooth muscle contraction | 9.93E-03 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
| Gabapentin | hsa04340 | Hedgehog signaling pathway | 1.80E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | |
| Gabapentin | hsa04371 | Apelin signaling pathway | 1.09E-03 | 4 | P31751, Q08828, P51828, P0DP23 | AKT2, ADCY1, ADCY7, CALM1 | More | |
| Gabapentin | hsa04380 | Osteoclast differentiation | 6.51E-03 | 3 | Q9NQC7, P23458, P31751 | CYLD, JAK1, AKT2 | More | |
| Gabapentin | hsa04512 | ECM-receptor interaction | 4.78E-02 | 1 | Q16787 | LAMA3 | More | |
| Gabapentin | hsa04540 | Gap junction | 3.73E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
| Gabapentin | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | |
| Gabapentin | hsa04611 | Platelet activation | 5.11E-03 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
| Gabapentin | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Gabapentin | hsa04625 | C-type lectin receptor signaling pathway | 3.91E-03 | 3 | Q9NQC7, P31751, P0DP23 | CYLD, AKT2, CALM1 | More | |
| Gabapentin | hsa04630 | JAK-STAT signaling pathway | 2.91E-03 | 3 | P31751, P23458, Q13651 | AKT2, JAK1, IL10RA | More | |
| Gabapentin | hsa04650 | Natural killer cell mediated cytotoxicity | 1.64E-04 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | |
| Gabapentin | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Gabapentin | hsa04658 | Th1 and Th2 cell differentiation | 9.73E-03 | 6 | P20963, P09693, Q16539, P06239, Q9UL17, P13765 | CD247, CD3G, MAPK14, LCK, TBX21, HLA-DOB | More | |
| Gabapentin | hsa04659 | Th17 cell differentiation | 7.42E-03 | 7 | Q16539, P06239, P13765, P14778, Q9UL17, P09693, P20963 | MAPK14, LCK, HLA-DOB, IL1R1, TBX21, CD3G, CD247 | More | |
| Gabapentin | hsa04662 | B cell receptor signaling pathway | 2.41E-02 | 2 | P31751, P15498 | AKT2, VAV1 | More | |
| Gabapentin | hsa04664 | Fc epsilon RI signaling pathway | 2.41E-02 | 2 | P31751, P15498 | AKT2, VAV1 | More | |
| Gabapentin | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Gabapentin | hsa04713 | Circadian entrainment | 2.91E-03 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
| Gabapentin | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | |
| Gabapentin | hsa04720 | Long-term potentiation | 3.73E-02 | 2 | P0DP23, Q08828 | CALM1, ADCY1 | More | |
| Gabapentin | hsa04723 | Retrograde endocannabinoid signaling | 4.48E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
| Gabapentin | hsa04724 | Glutamatergic synapse | 3.73E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
| Gabapentin | hsa04725 | Cholinergic synapse | 3.34E-04 | 5 | Q08828, P51828, P18848, Q13557, P31751 | ADCY1, ADCY7, ATF4, CAMK2D, AKT2 | More | |
| Gabapentin | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | |
| Gabapentin | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.91E-03 | 3 | Q08828, P51828, P0DP23 | ADCY1, ADCY7, CALM1 | More | |
| Gabapentin | hsa04910 | Insulin signaling pathway | 3.04E-02 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
| Gabapentin | hsa04911 | Insulin secretion | 2.59E-05 | 5 | Q08828, P51828, Q99941, P18848, Q13557 | ADCY1, ADCY7, CREBL1, ATF4, CAMK2D | More | |
| Gabapentin | hsa04912 | GnRH signaling pathway | 3.34E-04 | 5 | Q08828, P51828, P18848, Q13557, P0DP23 | ADCY1, ADCY7, ATF4, CAMK2D, CALM1 | More | |
| Gabapentin | hsa04913 | Ovarian steroidogenesis | 1.67E-03 | 4 | P42330, Q08828, P51828, P22694 | AKR1C3, ADCY1, ADCY7, PRKACB | More | |
| Gabapentin | hsa04914 | Progesterone-mediated oocyte maturation | 6.51E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
| Gabapentin | hsa04915 | Estrogen signaling pathway | 2.31E-05 | 8 | Q99941, P18848, Q08828, P51828, P31751, P07900, P11142, P0DP23 | CREBL1, ATF4, ADCY1, ADCY7, AKT2, HSP90AA1, HSPA8, CALM1 | More | |
| Gabapentin | hsa04916 | Melanogenesis | 1.41E-03 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
| Gabapentin | hsa04918 | Thyroid hormone synthesis | 1.98E-04 | 5 | Q08828, P51828, Q99941, P18848, P02768 | ADCY1, ADCY7, CREBL1, ATF4, ALB | More | |
| Gabapentin | hsa04921 | Oxytocin signaling pathway | 1.42E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
| Gabapentin | hsa04923 | Regulation of lipolysis in adipocytes | 2.69E-04 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
| Gabapentin | hsa04924 | Renin secretion | 3.43E-03 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
| Gabapentin | hsa04925 | Aldosterone synthesis and secretion | 1.78E-05 | 6 | Q99941, P18848, Q08828, P51828, P0DP23, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, CALM1, CAMK2D | More | |
| Gabapentin | hsa04926 | Relaxin signaling pathway | 6.87E-05 | 8 | P31751, Q99941, P18848, P22694, P14780, Q08828, P51828, P30679 | AKT2, CREBL1, ATF4, PRKACB, MMP9, ADCY1, ADCY7, GNA15 | More | |
| Gabapentin | hsa04927 | Cortisol synthesis and secretion | 1.74E-05 | 5 | Q99941, P18848, Q08828, P51828, P22694 | CREBL1, ATF4, ADCY1, ADCY7, PRKACB | More | |
| Gabapentin | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.17E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
| Gabapentin | hsa04934 | Cushing syndrome | 1.10E-04 | 5 | Q99941, P18848, Q08828, P51828, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, CAMK2D | More | |
| Gabapentin | hsa04935 | Growth hormone synthesis, secretion and action | 5.35E-04 | 5 | Q08828, P51828, Q99941, P18848, P31751 | ADCY1, ADCY7, CREBL1, ATF4, AKT2 | More | |
| Gabapentin | hsa04970 | Salivary secretion | 8.44E-05 | 6 | P07550, Q08828, P51828, P22694, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, CALM1, CAMP | More | |
| Gabapentin | hsa04971 | Gastric acid secretion | 1.41E-03 | 3 | Q08828, P51828, P0DP23 | ADCY1, ADCY7, CALM1 | More | |
| Gabapentin | hsa04972 | Pancreatic secretion | 2.41E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
| Gabapentin | hsa04973 | Carbohydrate digestion and absorption | 2.41E-02 | 1 | P13866 | SLC5A1 | More | |
| Gabapentin | hsa04976 | Bile secretion | 1.91E-03 | 3 | Q08828, P51828, P13866 | ADCY1, ADCY7, SLC5A1 | More | |
| Gabapentin | hsa05016 | Huntington disease | 1.07E-02 | 3 | Q9GZM3, P52435, P55036 | POLR2J2, POLR2J, PSMD4 | More | |
| Gabapentin | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | |
| Gabapentin | hsa05031 | Amphetamine addiction | 8.84E-04 | 5 | Q13557, P22694, Q99941, P18848, Q13547 | CAMK2D, PRKACB, CREBL1, ATF4, HDAC1 | More | |
| Gabapentin | hsa05032 | Morphine addiction | 2.41E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
| Gabapentin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.89E-03 | 2 | Q99437, P41240 | ATP6V0B, CSK | More | |
| Gabapentin | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | |
| Gabapentin | hsa05135 | Yersinia infection | 2.24E-02 | 3 | Q14161, P15498, P31751 | GIT2, VAV1, AKT2 | More | |
| Gabapentin | hsa05142 | Chagas disease | 4.48E-02 | 2 | Q08828, P31751 | ADCY1, AKT2 | More | |
| Gabapentin | hsa05144 | Malaria | 1.22E-04 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | |
| Gabapentin | hsa05145 | Toxoplasmosis | 1.67E-02 | 3 | P23458, P31751, Q13651 | JAK1, AKT2, IL10RA | More | |
| Gabapentin | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Gabapentin | hsa05152 | Tuberculosis | 9.49E-03 | 4 | P0DP23, P23458, P31751, Q13651 | CALM1, JAK1, AKT2, IL10RA | More | |
| Gabapentin | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | |
| Gabapentin | hsa05163 | Human cytomegalovirus infection | 2.17E-04 | 6 | P31751, P0DP23, Q08828, P51828, P23458, Q13651 | AKT2, CALM1, ADCY1, ADCY7, JAK1, IL10RA | More | |
| Gabapentin | hsa05164 | Influenza A | 3.67E-02 | 3 | P31751, P23458, Q9UBU9 | AKT2, JAK1, NXF1 | More | |
| Gabapentin | hsa05166 | Human T-cell leukemia virus 1 infection | 3.02E-02 | 4 | P23458, Q08828, P51828, P31751 | JAK1, ADCY1, ADCY7, AKT2 | More | |
| Gabapentin | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.24E-02 | 3 | P31751, P23458, P0DP23 | AKT2, JAK1, CALM1 | More | |
| Gabapentin | hsa05168 | Herpes simplex virus 1 infection | 2.09E-02 | 4 | Q9UBU9, P23458, P31751, Q6NUN9 | NXF1, JAK1, AKT2, ZNF746 | More | |
| Gabapentin | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | |
| Gabapentin | hsa05200 | Pathways in cancer | 1.65E-02 | 5 | P23458, P31751, Q08828, P51828, P0DP23 | JAK1, AKT2, ADCY1, ADCY7, CALM1 | More | |
| Gabapentin | hsa05203 | Viral carcinogenesis | 1.46E-02 | 4 | Q99941, P18848, P27348, P61978 | CREBL1, ATF4, YWHAQ, HNRPK | More | |
| Gabapentin | hsa05205 | Proteoglycans in cancer | 4.79E-03 | 8 | P63261, P04637, P14780, P01375, P23588, Q06124, Q13635, P22694 | ACTG1, TP53, MMP9, TNF, EIF4B, PTPN11, PTCH1, PRKACB | More | |
| Gabapentin | hsa05211 | Renal cell carcinoma | 7.75E-03 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | |
| Gabapentin | hsa05212 | Pancreatic cancer | 1.33E-03 | 4 | P31751, P23458, P04637, P24522 | AKT2, JAK1, TP53, GADD45A | More | |
| Gabapentin | hsa05213 | Endometrial cancer | 2.60E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Gabapentin | hsa05214 | Glioma | 1.04E-03 | 4 | P0DP23, P31751, P04637, P24522 | CALM1, AKT2, TP53, GADD45A | More | |
| Gabapentin | hsa05216 | Thyroid cancer | 1.14E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Gabapentin | hsa05217 | Basal cell carcinoma | 2.06E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Gabapentin | hsa05218 | Melanoma | 1.14E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Gabapentin | hsa05220 | Chronic myeloid leukemia | 7.90E-03 | 3 | Q06124, P04637, P24522 | PTPN11, TP53, GADD45A | More | |
| Gabapentin | hsa05222 | Small cell lung cancer | 4.78E-02 | 1 | Q16787 | LAMA3 | More | |
| Gabapentin | hsa05223 | Non-small cell lung cancer | 3.19E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Gabapentin | hsa05224 | Breast cancer | 4.51E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Gabapentin | hsa05225 | Hepatocellular carcinoma | 3.30E-02 | 3 | P04637, P24522, P63261 | TP53, GADD45A, ACTG1 | More | |
| Gabapentin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.63E-03 | 7 | P31751, P20963, P09693, P06239, P23458, O60603, Q16539 | AKT2, CD247, CD3G, LCK, JAK1, TLR2, MAPK14 | More | |
| Gabapentin | hsa05321 | Inflammatory bowel disease | 3.02E-03 | 4 | O60603, P01375, Q14765, Q9UL17 | TLR2, TNF, STAT4, TBX21 | More | |
| Gabapentin | hsa05332 | Graft-versus-host disease | 4.96E-04 | 4 | P10747, P01375, P26715, Q13241 | CD28, TNF, KLRC1, KLRD1 | More | |
| Gabapentin | hsa05414 | Dilated cardiomyopathy | 4.48E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
